Actively Recruiting
Observing Glofitamab Treatment in Chinese Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After One Prior Therapy
Led by Hoffmann-La Roche · Updated on 2026-08-06
300
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how well glofitamab-based therapy works and how safe it is in Chinese adults diagnosed with relapsed or refractory diffuse large B-cell lymphoma RR DLBCL who have already undergone one prior systemic therapy. This observational study focuses on adult participants receiving second-line treatment with glofitamab in a real-world clinical setting. Participants will be enrolled either before starting glofitamab therapy or within 90 days after beginning treatment. The study does not administer the treatment itself but observes patients treated with glofitamab as part of their cancer care. Throughout up to approximately four years, researchers will monitor participants to measure progression-free survival and several other outcomes such as response rates, duration of response, overall survival, and time to next treatment. Data collection will rely on medical records and observations without additional interventions, and safety and effectiveness will be assessed based on real-world clinical outcomes.
CONDITIONS
Brief Title
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Research Team
R
Reference Study ID Number: ML45172 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
